# Combination Camrelizumab (SHR-1210) and Apatinib for Downstaging/Bridging of HCC Before Liver Transplant

> **NCT04035876** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Zhejiang University** · enrollment: 120 (estimated)

## Conditions studied

- Hepatocellular Carcinoma
- Liver Transplant

## Interventions

- **DRUG:** Camrelizumab plus apatinib

## Key facts

- **NCT ID:** NCT04035876
- **Lead sponsor:** Zhejiang University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-07-16
- **Primary completion:** 2021-12-31
- **Final completion:** 2021-12-31
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2019-07-29

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04035876

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04035876, "Combination Camrelizumab (SHR-1210) and Apatinib for Downstaging/Bridging of HCC Before Liver Transplant". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT04035876. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*